ARTICLE | Company News
FDA approves Vernalis' Tuzistra XR
May 2, 2015 12:50 AM UTC
Vernalis plc (LSE:VER) said FDA approved Tuzistra XR to treat cough and common cold symptoms in adults. The product is an extended-release formulation of codeine polistirex and chlorpheniramine polistirex using the OralXR+ extended release formulation technology from Tris Pharma Inc. (Monmouth Junction, N.J.).
In a presentation discussing the approval, Vernalis said it will be ready to launch the product by the start of cold season in September. ...